Hydroxychloroquine dose based upon weight and renal function

Discussion in 'Chloroquine Drug' started by diamond_dt, 27-Feb-2020.

  1. greenapple Well-Known Member

    Hydroxychloroquine dose based upon weight and renal function


    Falciparum Discontinue in 6 months if improvement is inadequate Use in patients with psoriasis may precipitate a severe attack of psoriasis; use with caution Postmarketing cases of life-threatening and fatal cardiomyopathy reported with use of hydroxychloroquine as well as of chloroquine Irreversible retinal damage observed in some patients who had received hydroxychloroquine sulfate; significant risk factors for retinal damage include daily doses of hydroxychloroquine sulfate greater than 6.5 mg/kg (5 mg/kg base) of actual body weight, durations of use greater than five years, subnormal glomerular filtration, use of some concomitant drug products such as tamoxifen citrate and concurrent macular disease Ocular examination is recommended within first year of therapy; baseline exam should include: best corrected distance visual acuity (BCVA), an automated threshold visual field (VF) of the central 10 degrees (with retesting if an abnormality is noted), and spectral domain ocular coherence tomography (SD-OCT) For individuals with significant risk factors (daily dose of hydroxychloroquine sulfate 5.0 mg/kg base of actual body weight, subnormal glomerular filtration, use of tamoxifen citrate or concurrent macular disease) monitoring should include annual examinations which include BCVA, VF and SD-OCT; for individuals without significant risk factors, annual exams can usually be deferred until five years of treatment In individuals of Asian descent, retinal toxicity may first be noticed outside macula; in patients of Asian descent, it is recommended that visual field testing be performed in central 24 degrees instead of central 10 degrees Hydroxychloroquine should be discontinued if ocular toxicity is suspected and patient should be closely observed given that retinal changes (and visual disturbances) may progress even after cessation of therapy Hepatic disease or alcoholism Glucose-6-phosphate dehydrogenase (G6PD) deficiency is associated with hemolysis and renal impairment; use with caution Dermatologic reactions to hydroxychloroquine may occur Patients are prone to dermatitis outbreaks Signs or symptoms of cardiac compromise have appeared during acute and chronic treatment; clinical monitoring for signs and symptoms of cardiomyopathy is advised, including use of appropriate diagnostic tools such as ECG to monitor patients for cardiomyopathy during therapy; if cardiotoxicity is suspected, prompt discontinuation may prevent life-threatening complications Not for administration with other drugs that have potential to prolong QT interval; hydroxychloroquine prolongs QT interval; ventricular arrhythmias and torsades de pointes reported in patients taking hydroxychloroquine Skeletal muscle myopathy or neuropathy leading to progressive weakness and atrophy of proximal muscle groups, depressed tendon reflexes, and abnormal nerve conduction, reported; muscle and nerve biopsies have been associated with curvilinear bodies and muscle fiber atrophy with vacuolar changes; assess muscle strength and deep tendon reflexes periodically in patients on long-term therapy Suicidal behavior rarely reported in patients treated with hydroxychloroquine Hematologic reactions (including aplastic anemia) and agranulocytosis may occur May exacerbate heart failure Shown to cause severe hypoglycemia including loss of consciousness that could be life threatening in patients treated with or without antidiabetic medications; warn patients about risk of hypoglycemia and associated clinical signs and symptoms; patients presenting with clinical symptoms suggestive of hypoglycemia during treatment should have their blood glucose checked and treatment reviewed as necessary A reduction in dosage may be necessary in patients with hepatic or renal disease, as well as in those taking medicines known to affect these organs Use with caution in patients with hepatic disease or alcoholism or in conjunction with known hepatotoxic drugs Consider discontinuing therapy if any severe blood disorder such as aplastic anemia, agranulocytosis, leukopenia, or thrombocytopenia, which is not attributable to the disease under treatment appears; perform periodic blood cell counts if patients are given prolonged therapy Pregnancy category: C Lactation: Drug is concentrated in breast milk (American Academy of Pediatrics committee states that it is compatible with nursing) A: Generally acceptable. Contact the applicable plan provider for the most current information. Controlled studies in pregnant women show no evidence of fetal risk. Either animal studies show no risk but human studies not available or animal studies showed minor risks and human studies done and showed no risk. Animal studies show risk and human studies not available or neither animal nor human studies done.

    Plaquenil skutki uboczne Acr plaquenil Plaquenil and bariatric surgery

    Abstract. Background The American Academy of Ophthalmology recommendations on screening for chloroquine CQ and hydroxychloroquine HCQ retinopathy are revised in light of new information about the prevalence of toxicity, risk factors, fundus distribution, and effectiveness of screening tools. Pattern of Retinopathy Although the locus of toxic damage is parafoveal in many eyes, Asian. All patients in the cohort were prescribed hydroxychloroquine not to exceed a dose of 6.5 mg per kilogram. The maximum daily dose prescribed is 400 mg. In those who are on hemodialysis 200 mg was prescribed after each dialysis session. In those with renal insufficiency, the dose was 200mg daily. Annual screening may be commenced before 5 years of treatment if additional risk factors for retinal toxicity exist, such as concomitant tamoxifen therapy, impaired renal function eGFR less than 60 mL/minute/1.73 m 2 or high-dose therapy greater than 5 mg/kg/day of hydroxychloroquine sulfate.

    Unknown; may impair complement-dependent antigen-antibody reactions; inhibits locomotion of neutrophils and chemotaxis of eosinophils Increases p H and interferes with lysosomal degradation of hemoglobin, which in turn interferes with digestive vacuole function Bioavailability: Rapid and complete absorption Onset: May take 4-6 months to show response; peak response takes several months (rheumatic disease) Duration: Unknown Peak plasma time: 1-3 hr Protein bound: 55% Metabolites: Desethylhydroxychloroquine, desethylchloroquine Half-life: 32-50 days Excretion: Urine (60%) The above information is provided for general informational and educational purposes only. D: Use in LIFE-THREATENING emergencies when no safer drug available.

    Hydroxychloroquine dose based upon weight and renal function

    Hydroxychloroquine Blood Levels in Systemic Lupus., Hydroxychloroquine Blood Levels in SLE Clarifying dosing.

  2. Abruptly stopping plaquenil
  3. Hydroxychloroquine methotrexate sulfasalazine azathioprine lefludomide
  4. Can i immediately stop plaquenil
  5. Cdc chloroquine
  6. Dosages of drugs cleared renally are based on renal function calculated as GFR or creati-nine clearance; Table 3. These calculations are valid only when renal function is stable

    • Drug Dosing Adjustments in Patients with Chronic Kidney Disease.
    • HYDROXYCHLOROQUINE SULFATE Drug BNF content published..
    • Renal Function-Based Dose Adjustments - Adult - Inpatient..

    Regarding the dosing of hydroxychloroquine, we advocate the use of a weight-based dosing regimen with a cap at 400 mg per day, except in the case of renal insufficiency, when the dose should be reduced to 200 mg per day and for those on dialysis, who should take their hydroxychloroquine at 200 mg three times per week. Blood, renal tissue and spleen tissue sample collection and preparation. Following 8 weeks of treatment the mice were anesthetized using ether initial concentration, 10–15%; maintenance, 3–5% in an anesthesia device and then sacrificed by cervical dislocation, blood was collected from the eyes. A risk factor for Plaquenil hydroxychloroquine retinotoxicity is a daily dose that exceeds 5.0 mg of drug per kg of body weight. The tool on the right simply calculates this threshold based on a ppatient’s real body weight. It’s important to understand that the daily dose is only one risk factor for plaquenil retinotoxicity.

     
  7. FeSSik User

    Applies to hydroxychloroquine: oral tablet Along with its needed effects, hydroxychloroquine may cause some unwanted effects. Common and Rare Side Effects for Plaquenil Oral PLAQUENIL" Rheumatoid Arthritis Community - Support Group Hydroxychloroquine plaquenil ProHealth Fibromyalgia, ME.
     
  8. avernik User

    Graff, MD February 21, 2005 Chief Complaint: Patient on Amiodarone therapy. History of Present Illness: 54-year-old white male with a known history of atrial fibrillation and hypertension. There are dozens of medications, materials, and disease biproducts that can result in deposits in the cornea. Chloroquine And Hydroxychloroquine Toxicity - Abstract. Ocular Side effects of Oral Medications Flashcards Quizlet In vivo confocal microscopy in hydroxychloroquine- induced.
     
  9. dave XenForo Moderator

    Hydroxychloroquine Plaquenil Side Effects & Dosage for Malaria Hydroxychloroquine Plaquenil is a drug that is classified as an anti-malarial drug. Plaquenil is prescribed for the treatment or prevention of malaria. It is also prescribed for the treatment of rheumatoid arthritis, lupus, and the side effects of lupus such as hair loss, joint pain, and more.

    Treating Lupus with Anti-Malarial Drugs Johns Hopkins Lupus.